Testosterone Enanthate: What to Expect, Week-by-Week First Month

How Testosterone Enanthate Works Pharmacologically

Testosterone enanthate is testosterone attached to an enanthate ester, which slows release from the injection depot. Once the ester is cleaved by plasma and tissue esterases, free testosterone enters circulation and binds androgen receptors throughout the body. The half-life of TE is approximately 4.5 days, meaning a single 200 mg injection sustains elevated testosterone for roughly 10 to 14 days before returning toward baseline [1].

Ester Cleavage and Absorption

After intramuscular or subcutaneous injection, TE forms an oil depot at the injection site. Esterases cleave the enanthate chain over the following days, releasing free testosterone in a gradual curve. Serum testosterone peaks within 24 to 72 hours and then declines in a predictable exponential pattern [2].

Steady-State Kinetics

Steady state is reached after approximately 4 to 5 half-lives, placing it at roughly 3 to 4 weeks of consistent weekly dosing. Before steady state, each injection adds testosterone on top of residual levels from prior doses. This cumulative buildup explains why many patients feel a meaningful shift in energy and mood between weeks 3 and 5, not week 1 [3].

Why Peak-to-Trough Ratio Matters

A weekly 200 mg injection produces a higher peak-to-trough swing than the same total dose split into twice-weekly injections of 100 mg. A wider swing means higher estradiol at peak and lower testosterone at trough, which can cause mood variability, water retention, and libido fluctuation. The Endocrine Society Clinical Practice Guideline recommends maintaining trough testosterone above 300 ng/dL to avoid symptomatic deficiency between doses [4].

Week 1: The Injection Depot Loads

During the first week, serum testosterone rises sharply from its pre-treatment baseline. Men who were severely hypogonadal (total T <200 ng/dL) may notice a rapid shift in mood or sexual thoughts within 48 to 72 hours of injection [5]. This early response is real but not yet stable.

What You May Feel

• Injection-site soreness lasting 1 to 3 days, especially with sesame-oil vehicles
• A subtle rise in energy or mood by day 2 to 4 in men who started from very low baselines
• Possible mild water retention as testosterone begins converting to estradiol via aromatase
• No change in muscle size or strength, anabolic remodeling has not had time to begin

What the Labs Show

A serum testosterone drawn 48 to 72 hours post-injection will likely show supraphysiologic levels (800 to 1,200 ng/dL on a 200 mg dose). This peak reading does not represent your steady-state level and should not be used to make dose adjustments. Wait until week 6 to 8 trough labs for clinical decisions [4].

Injection Technique

Proper IM injection into the vastus lateralis or ventrogluteal site reduces post-injection pain. A 25-gauge, 1-inch needle suffices for most men using SubQ administration into the abdomen or lateral thigh. SubQ delivery produces a slightly blunted but more sustained absorption curve compared with IM, which may reduce peak-to-trough swings [6].

Week 2: Residual Depot Sustains Levels

By day 7 to 10, serum testosterone begins declining toward trough. Men on a 14-day injection schedule may notice fatigue, reduced libido, or mood dip in this window. This "trough effect" is one of the most common reasons patients switch from biweekly to weekly injections [7].

The Trough Experience

Men who started on a 200 mg every-14-day protocol often describe day 10 to 13 as the hardest stretch of their first month. Energy drops, sleep may worsen, and the libido gains from week 1 can reverse partially. This is a pharmacokinetic issue, not treatment failure.

Managing Week-2 Variability

Splitting the same total dose into weekly injections (100 mg/week instead of 200 mg every 2 weeks) dramatically narrows the peak-to-trough swing. A 2021 cross-over study published in the Journal of Clinical Endocrinology and Metabolism found that more frequent dosing intervals significantly reduced intra-individual testosterone variability while maintaining equivalent mean serum levels [7].

Estradiol in Week 2

Aromatase converts testosterone to estradiol in adipose, liver, and muscle tissue. In week 2, estradiol levels are rising alongside testosterone. A serum estradiol (sensitive assay) of 20 to 40 pg/mL is generally well-tolerated in men. Values above 60 pg/mL may produce nipple sensitivity, water retention, or emotional lability. Routine estradiol testing at baseline and at the first follow-up visit guides aromatase inhibitor decisions [8].

Week 3: Early Physiologic Effects Begin

Week 3 marks the transition from pure pharmacokinetic loading to early physiologic response. With consistent weekly dosing, testosterone levels are now approaching steady state. Many men report their first clear subjective improvements here, libido returns more reliably, morning erections resume, and sleep quality often improves [9].

Sexual Function Recovery

The T-Trials, a landmark set of coordinated randomized controlled trials published in the New England Journal of Medicine in 2016 (N=788 men aged 65 and older with documented hypogonadism), found that testosterone treatment produced a statistically significant improvement in sexual activity, sexual desire, and erectile function compared with placebo at 12 months [10]. The early signal for libido in clinical practice typically appears between weeks 2 and 4 in younger men with more severe deficiency.

Energy and Vitality

The T-Trials Vitality Trial component found a statistically significant improvement in fatigue and energy scores with testosterone versus placebo (P<0.001) [10]. Week 3 is often when patients first report that they feel "less flat" rather than dramatically energized. Full vitality restoration takes months, not weeks.

Mood and Cognition

Testosterone modulates dopaminergic and serotonergic pathways. Early improvements in irritability and depressive symptoms can appear by week 3, though the relationship between testosterone and mood is bi-directional. Men with pre-existing depression should continue any prescribed psychiatric medications without interruption during TRT initiation [11].

Week 4: Approaching Steady State and First Clinical Assessment

By the end of week 4, steady-state testosterone levels are nearly established on a weekly injection protocol. This is a clinically meaningful milestone. Symptom gains become more consistent, and the wide mood swings of weeks 1 to 2 tend to stabilize [3].

What Changes by Week 4

• Libido: noticeably improved in most men who started below 300 ng/dL
• Morning erections: returning in frequency and firmness for most patients
• Energy: moderate improvement; full recovery takes 3 to 6 months per Endocrine Society guidelines [4]
• Muscle: minimal visible change; protein synthesis is upregulated, but hypertrophy requires weeks of resistance training on top of hormonal optimization
• Body fat: no meaningful change yet; redistribution of fat mass takes 3 to 6 months [4]
• Hematocrit: rising modestly, generally still within normal range at week 4

What Has Not Changed Yet

Bone mineral density, spermatogenesis, prostate-specific antigen stabilization, and full cardiovascular adaptation all require months of treatment. Setting realistic expectations here prevents early discontinuation.

The Week-4 Check-In

Many TRT prescribers schedule a brief check-in call or telehealth visit around week 4. This is not a full lab visit but an opportunity to identify injection-site complications, severe mood changes, or cardiovascular symptoms that warrant early intervention [12].

Lab Monitoring in the First Month

Appropriate laboratory monitoring is a non-negotiable part of safe testosterone therapy. The American Urological Association 2022 guideline specifies that follow-up labs should be drawn at trough (immediately before the next scheduled injection) after 6 to 8 weeks of stable dosing [12].

Baseline Labs Before the First Injection

The AUA guideline recommends confirming hypogonadism with two morning serum total testosterone measurements below 300 ng/dL before starting therapy [12]. Additional baseline tests include:

• Free testosterone (calculated or equilibrium dialysis)
• LH and FSH (to distinguish primary from secondary hypogonadism)
• Hematocrit and hemoglobin
• PSA (men 40 and older, or at elevated prostate-cancer risk)
• Lipid panel and fasting glucose
• Estradiol (sensitive LC-MS/MS assay)
• Comprehensive metabolic panel

Trough Lab Targets at 6 to 8 Weeks

| Lab | Target Range | |---|---| | Total testosterone (trough) | 400 to 700 ng/dL | | Free testosterone | 10 to 25 ng/dL (calculated) | | Estradiol (sensitive assay) | 20 to 40 pg/mL | | Hematocrit | <54% | | PSA | <4 ng/mL or <1.4 ng/mL rise from baseline |

Hematocrit above 54% is the most common laboratory reason to reduce dose or increase injection frequency [4]. Polycythemia raises blood viscosity and carries a small but real thrombotic risk.

When to Draw Labs During Month 1

Do not draw testosterone levels at peak (24 to 72 hours post-injection) and use the result to judge dose adequacy. Peak levels consistently overestimate average exposure. Trough levels, drawn immediately before the next injection, are the gold standard for dose titration in all current guidelines [4, 12].

Side Effects Most Likely in the First Month

The side effects most likely to appear in the first month cluster into three categories: injection-site reactions, estrogenic effects, and hematologic changes. Later-emerging risks (cardiovascular, prostate, fertility) require longer exposure before meaningful monitoring.

Injection-Site Reactions

Pain, swelling, and induration at the injection site affect a meaningful proportion of new TE users. Rotating sites, warming the oil to body temperature before injection, and injecting slowly (over 30 to 60 seconds) reduce local reactions. Nodules or persistent pain lasting more than 5 days warrant clinical evaluation to rule out abscess [13].

Estrogenic Side Effects

Gynecomastia (breast tissue proliferation) and nipple tenderness are the most common estrogen-related complaints in month 1. The risk is higher in men with elevated baseline BMI, given that adipose tissue contains more aromatase. A serum estradiol above 60 pg/mL in a symptomatic man is a reasonable threshold to discuss aromatase inhibitor (anastrozole 0.25 to 0.5 mg twice weekly) use with a prescriber [8]. Routine prophylactic use of aromatase inhibitors is not recommended by the Endocrine Society [4].

Hematologic Changes

Testosterone stimulates erythropoietin production and increases red cell mass. Hematocrit begins rising within the first 2 to 4 weeks, though clinically significant polycythemia (hematocrit >54%) more often appears after 3 to 6 months. Baseline hematocrit above 48% deserves closer early monitoring [14].

Acne and Seborrhea

Increased sebum production from testosterone-stimulated sebaceous glands can cause facial and back acne in weeks 2 to 4. Mild cases respond to benzoyl peroxide or salicylic acid washes. Severe nodular acne warrants dermatology referral and possible dose reduction [15].

Testicular Atrophy

Exogenous testosterone suppresses LH and FSH through negative feedback on the hypothalamic-pituitary axis. Testicular volume reduction begins within the first month and is progressive with continued therapy. Men who wish to preserve fertility should discuss human chorionic gonadotropin (hCG) co-administration before starting TE [16].

Cardiovascular Considerations in Month 1

The cardiovascular safety of testosterone therapy remains an active area of research. The TRAVERSE trial (N=5,246, published in NEJM 2023) found no statistically significant increase in major adverse cardiovascular events (MACE) in hypogonadal men with pre-existing cardiovascular disease or high cardiovascular risk treated with testosterone undecanoate compared with placebo over a mean follow-up of 33 months [17]. The trial did find a higher rate of atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone group, which informs prescribing caution in high-risk patients.

Blood Pressure

Testosterone can raise blood pressure modestly through sodium and water retention in the first weeks of therapy. Men with poorly controlled hypertension (systolic >160 mmHg) should have blood pressure stabilized before starting TRT [12].

Polycythemia and Clot Risk

Hematocrit elevation beyond 54% is associated with increased blood viscosity and a theoretical increased risk of venous thromboembolism. The FDA mandates a boxed warning on all testosterone products regarding VTE risk [18]. Clinicians should obtain a personal and family history of thrombophilia before initiating therapy.

Fertility and Spermatogenesis

Testosterone enanthate is not a contraceptive, but it reliably suppresses sperm production. LH suppression begins within days of the first injection, and spermatogenesis declines over the following weeks to months. In a WHO-sponsored multicenter trial, testosterone enanthate 200 mg weekly produced severe oligospermia (sperm concentration <1 million/mL) in approximately 65% of men within 6 months [16].

Men who plan future paternity should be counseled explicitly before starting TE. Options include sperm banking before treatment, co-administration of hCG (500 to 1,000 IU subcutaneously 2 to 3 times per week) to maintain intratesticular testosterone and partial spermatogenesis, or use of clomiphene or FSH supplementation [16].

Dosing Protocols in Month 1: Standard Approaches

The most common starting protocol in the United States is testosterone enanthate 100 to 200 mg intramuscularly or subcutaneously every 7 to 14 days, as outlined in both the AUA 2022 guideline and the Endocrine Society 2018 Clinical Practice Guideline [4, 12].

Weekly vs. Biweekly Injections

Weekly injections (100 mg/week) produce steadier serum levels than biweekly injections (200 mg every 2 weeks) at the same total monthly dose. Most contemporary telehealth and clinic-based TRT programs have moved to weekly dosing because of the improved symptom stability and patient satisfaction reported in observational cohorts [7].

Subcutaneous vs. Intramuscular

SubQ injection into abdominal or thigh fat produces a slightly slower absorption curve and lower peak levels compared with IM gluteal or vastus lateralis injection. A 2017 study in the Journal of Urology (N=400) found no statistically significant difference in mean trough testosterone, patient-reported symptom scores, or adverse events between SubQ and IM routes at 6 months [6]. SubQ injection is associated with less injection pain and broader patient acceptance.

Dose Adjustments

Dose adjustments based on first-month labs are uncommon if the starting dose was evidence-based. If trough testosterone at 6 to 8 weeks falls below 400 ng/dL, the prescriber may increase the dose by 25 to 50 mg per injection or increase injection frequency. If trough exceeds 700 ng/dL or hematocrit exceeds 54%, dose reduction is indicated [4].

Drug Interactions and Contraindications

Testosterone enanthate has several clinically meaningful interactions that prescribers should review before initiation [19].

Anticoagulants

Testosterone potentiates the anticoagulant effect of warfarin. Men on warfarin starting TRT require more frequent INR monitoring during the first 4 to 6 weeks, with dose adjustments as needed [19].

Insulin and Oral Hypoglycemics

Testosterone improves insulin sensitivity. Men with type 2 diabetes starting TRT may experience lower blood glucose and require reduced doses of insulin or oral agents. The TRAVERSE trial enrolled a substantial cohort of men with diabetes or prediabetes, and the testosterone group showed improved glycemic indices compared with placebo [17].

Absolute Contraindications

The AUA guideline lists breast cancer and prostate cancer as absolute contraindications to testosterone therapy [12]. Men with hematocrit above 54% at baseline, untreated severe obstructive sleep apnea, or active heart failure (New York Heart Association class III, IV) should not start TE until those conditions are addressed.

PSA Monitoring and Prostate Safety

Testosterone does not cause prostate cancer, but it may stimulate growth of pre-existing androgen-sensitive cells. The Endocrine Society guideline states: "We suggest measuring PSA levels at 3 to 6 months after starting testosterone therapy and then in accordance with evidence-based guidelines for prostate cancer screening" [4]. A PSA rise of more than 1.4 ng/mL above baseline within the first 12 months, or any PSA above 4 ng/mL, warrants urology referral [4].

Baseline PSA before the first injection is mandatory in men 40 and older or in any man at elevated prostate-cancer risk [12].

Practical Injection Guide for the First Month

Correct technique reduces pain, avoids complications, and improves absorption consistency.

1. Draw up the prescribed dose using an 18-gauge draw needle, then swap to a 25-gauge, 1-inch needle for SubQ or a 23-gauge, 1.5-inch needle for IM.
2. Warm the vial between your palms for 30 to 60 seconds to reduce oil viscosity.
3. Clean the injection site with an alcohol swab and allow it to air dry for 10 seconds.
4. Inject slowly over 30 to 60 seconds.
5. Apply gentle pressure with a clean gauze pad for 30 seconds post-injection.
6. Rotate sites weekly (left vs. Right abdomen for SubQ; left vs. Right vastus lateralis for IM).
7. Discard sharps in an approved sharps container. Many pharmacies offer free sharps disposal [20].